The life sciences industry has always been resilient against global macroeconomic, geopolitical, and regulatory changes. With the onset of COVID-19 and the spiraling demand for vaccines, the clinical trials and R&D spend of top biopharmas have been bullish. Enterprises have adopted innovative ways of conducting clinical trials (such as decentralized clinical trials). The regulators have also evolved with the changing times by adopting virtual/hybrid audits to meet the demand for daily doses.
The latest macroeconomic trends such as rising inflation and high interest rates have had a significant impact on the life sciences industry. The ongoing Russia-Ukraine war has compounded recessionary concerns. The US, in particular, faces further tests with the implementation of Inflation Reduction Act (IRA). Additionally, the pharmaceutical industry is expected to lose billions in the coming years due to impending patent cliffs.
Scope:
Industry: life sciences BPS
Geography: global
Contents:
This report provides a detailed analysis life sciences landscape and includes:
The deteriorating global macro-economic trends and the impact on the life sciences industry
A regulatory overhaul is forcing MedTech enterprises to change their operating models to remain relevant in a fast-evolving business landscape. Additionally, they need to build supply chain resiliency to battle supply shortages in the industry and…
